- August 27, 2022
- Posted by: Bastion team
- Category: World News
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.
TORONTO, Aug. 26, 2022 (GLOBE NEWSWIRE) — Hempsana Holdings Ltd. (the “Company” or “Hempsana”) today announced three and six months financial results for the period ended June 30, 2022.
Randy Ko, Hempsana’s CEO commented: “Despite production setbacks, the second quarter of 2022 was highlighted by the commercialization of cannabinol (“CBN”) with initial orders taking place in June and the successful launch of ufeelu Calm Drops that was made available to consumers in Ontario which has quickly become a top selling CBG/CBD oil extract in Ontario. In this increasing diverse and competitive market, we continue to focus on product quality and improving our operation capabilities of our core B2B products such as distillate and isolate formats of CBD, THC, CBG and now CBN. We continue to focus on consumer data driven insights, innovation and brand development to bring unique products to market and with sights on beginning production and distribution of six new SKUS in Q3 in the pre-roll, health and wellness categories through our newest brands that we have added to our product portfolio: 1337 Elite, Canna Relief, Caviar Gold, Cream of the Crop Therapeutics, Haven and Shyne Botanicals.”
Operational Highlights
-
Completion of first commercial run of CBN Distillate and…